Design and Evaluate Anticancer Potential of if Haloacetamidines- Dderived PAD4 Inhibitors

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 2011年台俄有機、藥物與生物化學交流暨藥物化學研討會 > Item 310902800/24200

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/24200

標題:	Design and Evaluate Anticancer Potential of if Haloacetamidines- Dderived PAD4 Inhibitors
作者:	Yuji Wang (王玉記) Pingxin Li Shu Wang Jing Hu Megan Fisher Kira Oshaben Na Zhao Gong Chen Yanming Wang
日期:	2011
上傳時間:	2011-06-23 14:56:56 (UTC+8)
摘要:	Histones play an important role in human cells by organizing DNA to form basic structural units of chromatin termed nucleosomes. One emerging strategies for cancer treatment is to target enzymes that covalently modify histones thereby regulating cell proliferation and death. For example, histone deacetylase (HDAC) inhibitor, SAHA (also called voriostat or Zolina), has been used successfully in clinical trials and approved by FDA as a monotherapy compound or in comibination with various anticancer drugs. We anticipate that our research will offer the chemical and biological groundworJc to develop a PAD4 inhibitor for cancer treatment in combination with other anticticancer drugs, especially with the HDAC inhibitor SAHA. So the lead compounds, Cl-amidine derivatives were synthesized using a newly designed solution-based method to improve the specificity and bioavailability of the inhibitors. We tested the anticancer activity of the PAD4 inhibitor Cl-amidine and its derivatives and their anticancer activity in combination with the HDAC inhibitor SAHA. Taken together, we identify PAD4 as a promising drug target for cancer treatment, suggesting that epigenetic mechanisms can be explored to develop novel strategies for cancer chemotherapy.
關聯:	2011年台俄有機、藥物與生物化學交流暨藥物化學研討會，起迄日：2011/04/06~2011/04/05，地點：溪頭台大實驗林
显示于类别:	[藥理學院] 2011年台俄有機、藥物與生物化學交流暨藥物化學研討會

文件中的档案:

档案	描述	大小	格式	浏览次数
op-12.pdf		90Kb	Adobe PDF	654	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....